Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of OrallyAdministered ALS-008176 Regimens in Infants and Children Aged 1 to 36 Months Hospitalized with Respiratory Syncytial Virus

Next Previous
X
Search
Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of OrallyAdministered ALS-008176 Regimens in Infants and Children Aged 1 to 36 Months Hospitalized with Respiratory Syncytial Virus

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumicitabine (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Pharmacokinetics
  • Acronyms PLUM
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 10 May 2019 This trial has been completed in Germany, according to European Clinical Trials Database.
    • 26 Oct 2018 Status changed from recruiting to discontinued.
    • 05 Jun 2018 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top